Regdanvimab is a human monoclonal antibody that targets the SARS-CoV-2 spike protein. Regdanvimab is administered intravenously for the treatment of COVID-19.

**Magnitude of Teratogenic Risk to Child Born After Exposure During Gestation:** UNDETERMINED

**Quality and Quantity of Data on Which Risk Estimate is Based:** NONE

**Comments:** BECAUSE REGDANVIMAB IS AN ANTIBODY, IT MAY BE ACTIVELY TRANSPORTED ACROSS THE PLACENTA IN LATER PREGNANCY.

**Summary of Teratology Studies:**

**MAJOR CONGENITAL ANOMALIES**

No epidemiological studies of congenital anomalies among infants born to women who were treated with regdanvimab during pregnancy have been reported.

**ANIMAL TERATOLOGY STUDIES**

Animal teratology studies of regdanvimab conducted by the manufacturer have not been published in the peer-reviewed literature.

**Selected References:**

(Each paper is classified as a review [R], human case report [C], human epidemiological study [E], human clinical series [S], animal study [A], or other [O].)

None available.